Obesity and overweight with comorbidities
Amount
Up to 4.8 mg
Frequency
Once weekly
Duration
16 doses (Phase 1b)
Route
SCSchedule
Once weekly
Timing
Dose escalation protocol used in Phase 1b; ZUPREME Phase 2b trials evaluating optimized dosing
Duration
Ongoing (long-term use intended)
Repeatable
Yes
Fasting glucose and HbA1c
When: Baseline
Why: Baseline glycemic status
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk markers
Fasting glucose and HbA1c
When: 12 weeks
Why: Monitor glycemic changes
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Petrelintide (ZP8396) is a long-acting amylin analog developed by Zealand Pharma. Amylin is a pancreatic hormone co-secreted with insulin that promotes satiety, slows gastric emptying, and reduces glucagon secretion. Petrelintide is a 36-amino acid peptide with fatty acid acylation enabling once-weekly subcutaneous dosing. In March 2025, Roche acquired global rights in a deal worth up to $5.3 billion.
Petrelintide activates amylin receptors (AMY1, AMY2, AMY3) in the area postrema and other brainstem regions to reduce food intake. It also restores leptin sensitivity, a key feature for sustained weight loss. Unlike GLP-1 agonists, which primarily signal through a single receptor, amylin analogs engage a distinct appetite-regulation pathway, making them attractive candidates for combination therapy.
Phase 1b results demonstrated 8.6% weight loss at the 4.8 mg dose over 16 once-weekly injections, with good tolerability. Phase 2b ZUPREME-1 and ZUPREME-2 trials are currently enrolling, evaluating petrelintide both as monotherapy and in combination with GLP-1 receptor agonists.
Petrelintide is investigational and not approved by any regulatory authority. Clinical data are limited to Phase 1b results. The ZUPREME Phase 2b program will provide more comprehensive efficacy and safety data.
Phase 1b Study of Petrelintide in Adults with Overweight or Obesity, published in Conference presentation (Zealand Pharma) (Zealand Pharma investigators, 2024):
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
0View community protocolsSemaglutide: FDA-approved GLP-1 agonist for weight loss and diabetes. Covers STEP/SUSTAIN trials, Ozempic vs Wegovy dosing, and cardiovascular benefits.
Tirzepatide: FDA-approved dual GIP/GLP-1 agonist with up to 22.5% weight loss. Covers SURPASS/SURMOUNT trials, dosing, and semaglutide comparison.
Cagrilintide: Long-acting amylin analog for obesity. Covers satiety mechanism, CagriSema combination data, Phase 3 results, dosing, and side effects.
Eloralintide (LY3841136): selective long-acting amylin receptor agonist with up to 20.1% weight loss in Phase 2. Eli Lilly Phase 3 enrolling 2026.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
A research review of GLP-1 and amylin combination therapy for obesity, covering CagriSema, amycretin, petrelintide, pramlintide, and the science behind dual appetite hormone targeting.
A research review of non-GLP-1 peptide approaches to weight loss โ amylin analogs (cagrilintide, petrelintide, pramlintide), melanocortin agonists (setmelanotide, bivamelagon), and anti-myostatin antibodies (bimagrumab).
Related content you may find interesting